本文已被:浏览 705次 下载 507次
Received:March 03, 2023 Published Online:April 20, 2023
Received:March 03, 2023 Published Online:April 20, 2023
中文摘要: 重症哮喘在所有哮喘患者中仅占一小部分,但却是其致残、致死的主要原因,给社会带来沉重的社会及经济负担。重症哮喘通常需要给予高剂量吸入皮质激素(ICS)和口服糖皮质激素治疗,上述治疗方法长期大量使用可引起一系列副作用。近年来,生物靶向治疗、支气管热成形术等新疗法不断发展,本文聚焦于重症哮喘治疗的现状及前景,以期为重症哮喘患者的个体化治疗提供参考依据。
Abstract:Severe asthma accounts for only a small proportion of all asthmatic patients, but its the main cause of disability and death of them, and brings heavy social and economic burden to the society. Severe asthma usually requires high-dose inhaled corticosteroid(ICS) and oral corticosteroids, which can cause a series of side effects. In recent years, new therapies such as biotargeted therapy and bronchial thermoplasty have continued to develop. This review summarizes status and prospects in treatment of severe asthma, aiming to provide a reference for personalized treatment and improvement of quality of life in severe asthma patients.
文章编号: 中图分类号:R562.2+5 文献标志码:A
基金项目:
引用文本: